Starting from these values (column 3 (x)), and maintaining the ratio between element concentrations, we constructed a matrix calibration curve for four levels (8x/3,x,x/2,x/6), with a fixed level of Ra (33 fg g−1).
These factors include non-random genetic mutations producing chimeric RARα receptors with dominant negative function, such as the leukemia-associated PML-RARα and PLZF-RARα [9 and references within], RARα epigenetic silencing in epithelial cancer cells [10] [13], and a defective intracellular level of RA consequent to defects of the retinol/RA metabolism/homeostasis [4], [14] [17].
Variability is introduced at the level of RA by an external source of variable input (LMAN).
The DAS28 is a continuous scale ranging from 0 to 9.4, indicating level of RA disease activity.
We also explored whether differences in CAC between RA and control groups varied by gender, age, and level of RA severity.
Optimal clear reporting of any level of RA in RCTs and meta-analyses would improve the transparency of the studies and facilitate the replication of the results.
The mean C-reactive protein level of RA patients was 22.16 ± 18.85 mg/l, but the C-reactive protein values of OA patients were not determined.
The average disease duration was 11 to 12 years and the DAS28 score indicated that all these patients had a high level of RA activity, which fits with their resistance to one or more DMARDs.
In this study, we investigated whether HDL2-chol and HDL3-chol concentrations differ between RA patients and healthy controls, and whether these levels are related to the level of RA disease activity.
An important role for the level of RA availability is indicated by the finding that the number of OSNs expressing a specific OR was reduced in homozygous compared with hemizygous dnRAR transgenic mice.
Therefore, the objective of this study was to investigate whether HDL2-chol and HDL3-chol concentrations differ between RA patients and healthy controls, and to investigate whether HDL2-chol and HDL3-chol concentrations are associated with the level of RA disease activity.
